FDA Approves New Vaccine for Hepatitis B

The Hepatitis B Foundation applauds the U.S. Food and Drug Administration’s (FDA) approval of HEPLISAV-B™, the first new hepatitis B vaccine in more than 25 years and the only two-dose schedule for the prevention of infection in adults. “The new two-dose vaccine is a game changer,” said Timothy Block, PhD, president of the Hepatitis B Foundation. “Current vaccines require three doses over 6 months, which makes it hard for some people to get all doses. With the new vaccine, people can be fully protected with two doses, in just one month. As we work towards finding a cure and eliminating hepatitis B in the U.S. and globally, having this new tool in our arsenal will play a critical role in preventing infections.” Read more.

Comments are closed.